The hypocholesterolemic activities of 81 yeast strains were examined in rats fed a high cholesterol diet (HCD). Male Wistar rats were fed an HCD or an HCD supplemented with 10% yeast for 7 d. It was found that the hypocholesterolemic activities of the yeasts varied remarkably between strains. Kluyveromyces marxianus YIT 8292 exhibited the most potent hypocholesterolemic activity among the yeasts that were tested. K. marxianus YIT 8292 significantly decreased not only plasma total cholesterol but also liver total cholesterol when administered as a dietary admixture at a concentration of 3%. In contrast, brewer's yeast and baker's yeast, which have been predominantly used for food, did not exhibit hypocholesterolemic activity even when administered at a concentration of 10%. These results suggest that K. marxianus YIT 8292 may be utilized as a novel food material with the ability to contribute to the prevention of hypercholesterolemia.
Since the pioneering results of the Framingham study 1) were disclosed, hypercholesterolemia has been recognized as a major risk factor for the development of coronary heart disease. 2, 3) Lowering plasma cholesterol levels has proven to reduce mortality from myocardial infarction, 4) hence the search for natural substances capable of lowering plasma cholesterol is ongoing in the field of nutrition and medicine. Several food constituents have been reported to be effective in lowering plasma cholesterol in animals or humans. Examples include some dietary fibers, 5) plant sterols, 6) herbal extracts, 7) and some yeasts. [8] [9] [10] [11] [12] [13] Yeasts have diverse fermentative activities and therefore have been used for the production of many kinds of fermented food such as bread, beer, wine, and fermented milk. Dried yeasts (usually heat inactivated) have also been used as a nutrition supplement because whole yeast cells are rich in vitamin B, dietary fiber, and protein.
Three species of yeast, Saccharomyces cerevisiae, Candida utilis (also known as torula yeast), and
Kluyveromyces marxianus, are widely used as dried yeasts. 14) Recently, the beneficial effects of dried yeasts on health have been investigated. Previous studies have shown that some yeasts or their constituents exert hypocholesterolemic activity, [8] [9] [10] [11] [12] [13] 15) anti-tumor activity, 16) or immunostimulation activity, 17) or can prevent constipation 18) in animals or humans. In previous studies, 8, 9) it was reported that strains of S. cerevisiae (baker's yeast and brewer's yeast) and C. utilis decreased serum total cholesterol in rats fed a high cholesterol diet when administered as a dietary admixture at concentrations of 15 to 20%. Some reports [11] [12] [13] have shown that dietary supplements of brewer's yeast decreased serum total cholesterol in humans; however, because other studies [19] [20] [21] [22] failed to show such a beneficial effect, the true dietary effectiveness of such yeasts has not yet been fully clarified.
Although many strains of yeast are used in the food industry, their hypocholesterolemic activities have not been examined, with the exception of baker's yeast, brewer's yeast, and C. utilis. Therefore, it is possible that strains other than these three yeasts possess more potent hypocholesterolemic activity.
In the present study, we examined the hypocholesterolemic activities of 81 yeast strains that are used in the food industry in rats fed a high cholesterol diet (HCD), and chose the strain with the most potent hypocholesterolemic activity.
Materials and Methods
Yeast strains and cultivation. Baker's yeast was purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan). Brewer's yeast was kindly provided by Yakult Pharmaceutical Ind. Co., Ltd. (Tokyo, Japan). The other yeast strains were obtained from the Culture Collection Research Laboratory of the Yakult Central Institute for Microbiological Research (Tokyo, Japan) and grown in a medium of the following composition: 30 g glucose, 10 g polypeptone, 5 g yeast extract, 1 g KH 2 PO 4 , 2 g K 2 HPO 4 , 0.5 g MgSO 4Á 7H 2 O, and tap water to 1 liter. Yeast cells were inoculated into a 500-ml Sakaguchiy To whom correspondence should be addressed. Fax: +81-42-577-3020; E-mail: yasuto-yoshida@yakult.co.jp Abbreviations: HCD, high cholesterol diet; ND, normal diet; HDL, high density lipoprotein flask containing 100 ml of medium and incubated at 28 C on a reciprocal shaker at 120 strokes/min. After 24 h, 300 ml of the cultured broth was inoculated into a 10 liter fermentor containing 7 liters of medium. Cultivation was carried out for 24 h at 28 C, with agitation at 800 rpm and an aeration rate of 0.5 vvm. The pH was adjusted to 6.0 using 5 N NaOH. After cultivation, the yeast cells were harvested by centrifugation at 3,000 g for 10 min. The cells were washed twice with distilled water and then heated in an autoclave at 115 C for 10 min. After autoclaving, the whole cells were lyophilized and powdered. Each resulting dried yeast sample was analyzed for total dietary fiber, protein, fat, ash, and moisture. 23) Animals and diets. Five-week-old male Wistar rats were obtained from Clea Japan Inc. (Tokyo, Japan). Animal experiments were performed in accordance with the guidelines of the Ethical Committee for Animal Experiments of the Yakult Central Institute for Microbiological Research (Tokyo, Japan). The rats were individually housed in stainless steel cages in a temperature-controlled room (24 AE 1 C) at 60 AE 5% humidity under a 12 h light/12 h dark cycle. The rats were fed a commercial solid diet (MF; Oriental Yeast Co., Ltd., Tokyo, Japan) ad libitum during the acclimation period of 7 d. After the acclimation period, they were randomly divided into groups, each containing 8 rats. The animals were allowed free access to water throughout the experimental period.
The compositions of a normal diet (ND) and a high cholesterol diet (HCD) are shown in Table 1 . Each yeast was added to an HCD. In order to equalize the contents of fiber, protein, and fat in each diet, these constituents of the yeast replaced cellulose, casein, and lard respectively. The other constituents of the yeast (moisture, ash, and carbohydrate) replaced sucrose.
Experimental design. Three experiments were conducted to examine the hypocholesterolemic activities of the yeasts.
Experiment 1: The hypocholesterolemic activities of 81 yeast strains were studied in 12 separate tests. After the acclimation period, rats weighing 150$200 g were divided into groups (n ¼ 8) and then fed an ND, an HCD, or an HCD supplemented with 10% yeast ad libitum for 7 d. The food consumption of each rat was recorded every 2 or 3 d.
Experiment 2: Thirty-one strains were chosen on the basis of the results of experiment 1 and their hypocholesterolemic activities were examined at a lower dose. In this experiment, the daily intake for each diet was restricted to 15 g in order to equalize the input of dietary cholesterol. After the acclimation period, rats weighing 150$190 g were divided into groups (n ¼ 8) and then offered 15 g of an ND, an HCD, or an HCD supplemented with 5% yeast at 10 a.m. daily for 14 d. The food consumption of each rat was recorded every day.
Experiment 3: The effect of K. marxianus YIT 8292 on plasma and liver cholesterol levels was examined at various doses. The compositions of the experimental diets and yeasts which were used in this experiment are shown in Table 1 and Table 2 respectively. In this experiment, the daily intake for each diet was restricted to 15 g in the same manner as in experiment 2. After the acclimation period, rats weighing 160$180 g were divided into groups (n ¼ 8) and then offered 15 g of an ND, an HCD, or an HCD supplemented with yeast at 10 a.m. daily for 14 d.
In all experiments, the rats were anaesthetized with an intraperitoneal injection of sodium pentobarbital (Nembutal Ò , Abbot Laboratories, Chicago, Illinois, U.S.A.) at 10 a.m. on the last day of the experimental period, and blood samples were collected from the abdominal aorta. Blood from each rat was placed in a plastic tube containing heparin, and plasma was separated by centrifugation. The livers were perfused with 0.9% NaCl, removed, and weighed. The livers were lyophi- lized and powdered with a mill.
Biological Analysis. Total cholesterol, HDL-cholesterol, triglyceride, and phospholipid in the plasma were enzymatically measured with commercial kits (Determiner TC555, Kyowa Medics, Tokyo, Japan; Determiner HDL, Kyowa Medics; Triglyceride E test Wako, Wako Pure Chemical Industries, Tokyo, Japan; and Phospholipid B test Wako, Wako Pure Chemical Industries). [24] [25] [26] [27] Liver lipids were extracted by the methods of Folch et al. 28) and redissolved in ethanol. Liver total cholesterol, triglyceride, and phospholipid concentrations were measured enzymatically as described above. The hypocholesterolemic activity of the yeast, expressed as a lowering ratio of plasma total cholesterol (%), was calculated as follows:
Lowering ratio of plasma total cholesterol ð%Þ ¼ ½ðB À AÞ=ðB À CÞ Â 100 where A is the plasma total cholesterol of the rats fed an HCD supplemented with yeast, B is the average plasma total cholesterol of the rats fed an HCD, and C is the average plasma total cholesterol of the rats fed an ND.
Statistical methods. Data were expressed as mean AE standard deviation (SD). The data were analyzed using one-way analysis of variance (ANOVA). When a significant F ratio was found, Tukey's multiple-comparison tests were conducted. Differences were considered significant at p < 0:05. The SAS system for windows (release 6.12; SAS Institute Inc., Cary, North Carolina, U.S.A.) was employed as software for statistical analysis.
Results

Experiment 1: Comparison of the hypocholesterolemic activities of yeast strains in rats fed a high cholesterol diet
The hypocholesterolemic activities of 81 yeast strains were studied in 12 separate tests. Male Wistar rats were fed an ND, an HCD, or an HCD containing each yeast at a concentration of 10% ad libitum for 7 d, and the lowering ratios of plasma total cholesterol were compared.
In rats fed an HCD, the means of food consumption, body weight gain, and plasma total cholesterol were 146$162 g/7 d, 42.4$45.9 g/7 d and 224$259 mg/dl respectively. In rats fed an ND, the means of food consumption, body weight gain, and plasma total cholesterol were 148$166 g/7 d, 41.6$46.0 g/7 d and 53.9$67.2 mg/dl respectively.
As shown in Table 3 , the lowering ratios of plasma total cholesterol were remarkably different among the strains of yeast that were added to an HCD. Forty-eight strains significantly decreased plasma total cholesterol, but the other yeasts (including brewer's yeast, baker's yeast, and C. utilis YIT 8204) did not significantly alter plasma total cholesterol. All strains of K. marxianus (5 strains), Candida kefyr (3 strains), and Candida gropengiesseri (2 strains) significantly decreased plasma total cholesterol. Some strains of Pichia anomala (3 out of 4 strains), Saccharomyces bayanus (2 out of 4 strains), and Torulaspora delbrueckii (2 out of 6 strains) also significantly decreased plasma total cholesterol, but no strain of Zygosaccharomyces rouxii (2 strains) or Yarrowia lipolytica (2 strains) exhibited hypocholesterolemic activity.
Pichia subpelliculosa YIT 8303, Hyphopichia burtonii YIT 8299, Z. rouxii YIT 8317, Candida cylindracea YIT 8276, and Pichia farinosa YIT 8058 significantly decreased food consumption to 72.9%, 73.2%, 75.4%, 77.6% and 82.1% respectively, in rats fed an HCD. These yeasts also slightly decreased body weight gain, but the difference was not significant. The other yeasts did not significantly alter food consumption or body weight gain.
Experiment 2: Selection of yeast strains with potent hypocholesterolemic activity
Thirty-one yeast strains that exhibited potent hypocholesterolemic activity in experiment 1 were selected and their effects on plasma total cholesterol were further examined at a lower dose (5% yeast in an HCD) over a prolonged period (14 d) in 5 separate tests. In this experiment, the daily intake for each diet was restricted to 15 g in order to equalize the input of dietary cholesterol.
As a result, all rats completely consumed a daily diet throughout the experimental period. In the rats fed an HCD, the means of body weight gain and plasma total cholesterol were 51.0$58.1 g/14 d and 272$326 mg/dl respectively. In rats fed an ND, the means of body weight gain and plasma total cholesterol were 51.6$60.3 g/14 d and 52.9$59.7 mg/dl respectively.
Body weight gain was not significantly different among groups. As shown in Table 3 , 25 strains significantly decreased plasma total cholesterol when administered as a dietary admixture at a concentration of 5%. Among these strains, K. marxianus YIT 8292 exhibited the most potent hypocholesterolemic activity.
Experiment 3: Dose-dependent effect of K. marxianus YIT 8292 on plasma and liver cholesterol levels
In this experiment, the effect of various doses of K. marxianus YIT 8292 on plasma and liver lipid levels was examined and was compared with those of brewer's yeast, baker's yeast, and C. utilis YIT 8204.
Food intake, body weight gain, and liver weight are shown in Table 4 . All rats completely consumed a daily diet throughout the experimental period. Body weight gain did not differ among groups. The liver weight of rats fed a HCD was significantly higher than that in rats fed an ND. The addition of 10% K. marxianus YIT 8292 to an HCD significantly reduced liver weight.
Plasma and liver total cholesterol levels of rats fed an HCD were significantly higher than those in rats fed an ND (Fig. 1) . The addition of K. marxianus YIT 8292 to an HCD decreased levels of total cholesterol in the plasma and liver in a dose-dependent manner. These parameters were significantly lower in rats fed 3% or 10% K. marxianus YIT 8292 than in rats fed an HCD alone. The feeding of 10% brewer's yeast, 10% baker's yeast or 10% C. utilis YIT 8204 did not alter levels of total cholesterol in the plasma and liver. HDL-cholesterol was significantly lower in rats fed an HCD than in rats fed an ND (Fig. 1) . The addition of K. marxianus YIT 8292 to an HCD did not significantly alter HDLcholesterol.
Levels of triglyceride and phospholipid in the plasma and liver are shown in Table 5 . Plasma triglyceride did not differ among groups. The plasma phospholipid, liver triglyceride, and liver phospholipid of rats fed an HCD were significantly higher than those of rats fed an ND. The plasma phospholipid of rats fed an HCD containing 
HCD, high cholesterol diet; Nd, not determined.
In the column corresponding to experiment 1, strains are arranged in descending order of the lowering ratio of plasma total cholesterol. *, p < 0:05; **, p < 0:01 (Tukey's test; compared with control rats fed an HCD). 10% K. marxianus YIT 8292 was slightly lower than that of rats fed an HCD, but this difference was not significant. The addition of 10% K. marxianus YIT 8292 to an HCD significantly reduced levels of triglyceride and phospholipid in the liver.
Discussion
In this study, we investigated the hypocholesterolemic activities of yeasts under three different experimental designs. In experiment 1, rats were fed an ND, an HCD, or an HCD containing each yeast at a concentration of 10% ad libitum for 7 d and the hypocholesterolemic activities of the yeasts were compared. Although the majority of yeast strains did not alter food consumption, several strains, such as P. subpelliculosa YIT 8303 and H. burtonii YIT 8299, significantly decreased food consumption to 73$82% of that in rats fed an HCD. Therefore, in order to equalize the input of dietary cholesterol, the daily intake of each diet in experiments 2 and 3 was restricted to 15 g, which was equivalent to 70% of the daily intake of rats fed an HCD ad libitum. It is suggested that the restriction of food consumption caused a fasting state over the short term. Several yeasts that decreased food consumption might delay the time taken to consume a daily diet and might shorten the duration of fasting. But Guermani-Nicolle et al. 29) reported that fasting of up to 8 h did not alter the level of total serum cholesterol in rats fed an HCD. Therefore, we think that a difference in duration of short-term fasting had hardly any effect on plasma total cholesterol in experiments 2 and 3.
Our results show that the intensity of hypocholesterolemic activity was remarkably different among the yeast strains (Table 3) . Forty-eight strains decreased plasma total cholesterol when administered as a dietary admixture at a concentration of 10% ad libitum for 7 d, but 33 strains (including brewer's yeast, baker's yeast, and C. utilis YIT 8204) did not significantly alter plasma total cholesterol (Table 3) . A further 25 strains exhibited hypocholesterolemic activity even when administered as dietary admixtures at a concentration of 5% under the conditions of experiment 2 ( Table 3 ). All strains of K. marxianus (5 strains) efficiently lowered plasma total cholesterol when administered at a concentration of 5%. All strains of C. kefyr (3 strains) and of C. gropengiesseri (2 strains) exhibited hypocholesterolemic activity when administered at a concentration of 10%, but no strain of Z. rouxii (2 strains) or Y. lipolytica (2 strains) significantly decreased plasma total cholesterol when administered at a concentration of 10% (Table 3) . By comparison, among 6 strains of T. delbrueckii, 2 strains exhibited hypocholesterolemic activity when administered at a concentration of 10%, but the other 4 strains did not exhibit hypocholesterolemic activity (Table 3) . Similarly, the hypocholesterolemic activity of P. anomala and S. bayanus also differed among strains of the same species (Table 3) . These results show that the Table 1 and Materials and Methods. ND, normal diet; HCD, high cholesterol diet.
hypocholesterolemic activities of yeast vary depending on the species or strain.
Several previous studies [11] [12] [13] reported that ingestion of brewer's yeast decreased serum total cholesterol in humans, but other studies [19] [20] [21] [22] have failed to show such beneficial effects. At present, the reasons for this discrepancy are not clear, but two possibilities may be suggested based on our results. One possibility is that the discrepancy can be attributed to differences in the strain of brewer's yeast used in those trials. As described above, several yeasts exhibited different abilities to reduce plasma total cholesterol even between strains of the same species. Therefore, the hypocholesterolemic activities of brewer's yeast may also differ among strains. Another possibility is that the low potency of brewer's yeast in reducing plasma total cholesterol is the cause of the discrepancy. Previous studies [8] [9] [10] have shown that brewer's yeast, baker's yeast, and C. utilis exerted hypocholesterolemic effects in rats fed an HCD only when given at high doses. Robbins and Seeley 8, 9) reported that these yeasts significantly decreased serum total cholesterol when administered as a dietary admixture at a concentration of 15%. But Ebihara and Kiriyama 10) reported that brewer's yeast did not exhibit hypocholesterolemic activity when administered as a dietary admixture at a concentration of 5%, although plasma total cholesterol was significantly decreased by feeding a diet composed of 20% brewer's yeast. The brewer's yeast used in the present study did not exhibit hypocholesterolemic activity when administered at a concentration of 10% in an HCD. Therefore, the hypocholesterolemic activities of brewer's yeasts may be relatively low compared to those of other yeasts, even if activities differ between strains. By comparison, food materials such as psyllium and chitosan, whose efficiency has been shown reproducibly in humans, [30] [31] [32] exhibited hypocholesterolemic activities in rats fed an HCD when administered at a concentration of 5% or lower. [33] [34] [35] Therefore, it may be difficult to detect the effects of brewer's yeasts on serum cholesterol in humans at physiological doses. In this respect, it is necessary to examine differences in hypocholesterolemic activities among strains of brewer's yeast and to identify the effective dose.
It has been reported that some fractions prepared from brewer's yeast or baker's yeast, such as the cell wall fraction and -glucan from the cell wall, reduced blood cholesterol in rats [8] [9] [10] or humans. 15) The yeast cell wall is composed mainly of dietary fiber such as -glucan and -mannan. There is, however, little variation in the dietary fiber contents of the various yeast strains (Table 2) , and a defined correlation between the lowering ratios of plasma total cholesterol in experiment 1 (Table 3 ) and dietary fiber contents has not been observed for yeasts (r ¼ 0:198, p > 0:05). Therefore, the differences in hypocholesterolemic activities among yeasts cannot be accounted for by differences in dietary fiber contents. Differences in the structure or composition of dietary fiber, or in the contents of the other active compounds, may be involved in the variation of hypocholesterolemic activities. To clarify the reason for the differences in hypocholesterolemic activities, further studies to determine the active compound and the mechanism of the cholesterol lowering activity of the yeasts are needed.
Among the yeasts that were tested, K. marxianus YIT 8292 exhibited the most potent hypocholesterolemic activity (Table 3) . K. marxianus YIT 8292 decreased plasma total cholesterol and liver total cholesterol in a dose-dependent manner, and the decline in these values was significant even when it was administered as a dietary admixture at a concentration of 3% (Fig. 1) . Increases in liver weight and levels of triglyceride and phospholipid in the liver caused by feeding of a hypercholesterolemic diet were also partly suppressed when K. marxianus YIT 8292 was administered as a dietary admixture at a concentration of 10% (Table 4 and Table 5 ). K. marxianus is a representative species found in kefir grain. Kefir is a traditional fermented milk made from the milk of cows, goats, or sheep in Russia and the Caucasus. Belem and Lee outlined the following advantages of K. marxianus as a food material: 36) (1) good growth yield, which has an important impact on cost efficiency in the food industry; (2) acceptability as a safe microorganism; (3) it is a lactose fermentative yeast which can grow on whey waste; and (4) it is the only yeast permitted to be grown on whey in the U.S.A. 14) Therefore, K. marxianus YIT 8292 may be useful as a novel food material with the ability to contribute to the prevention of hypercholesterolemia.
